Combining insulins with oral antidiabetic agents: effect on hyperglycemic control, markers of cardiovascular risk and disease

References

• AhmedIGoldsteinBJCardiovascular risk in the spectrum of type 2 diabetes mellitusMt Sinai J Med2006737596817008936
   PubMedGoogle Scholar
• American Diabetes AssociationTreatment of hypertension in adults with diabetesDiabetes Care20022519920111772916
   PubMed Web of Science ®Google Scholar
• AvenaRMitchellMENylenESInsulin action enhancement normalizes brachial artery vasoactivity in patients with peripheral vascular disease and occult diabetesJ Vast Surg199828102431
   PubMed Web of Science ®Google Scholar
• BaileyCJDayCAntidiabetic drugsBr J Cardiol20031012836
   Google Scholar
• BakrisGVibertiGWestonWMRosiglitazone reduces urinary albumin excretion in type II diabetesJ Hum Hypertens2003175612571610
   PubMed Web of Science ®Google Scholar
• BoSCicconeGGanciaRMortality within the first 10 years of the disease in type 2 diabetic patientsNutr Metab Cardiovasc Dis20061681216399486
   PubMed Web of Science ®Google Scholar
• BoehmBOHomePDBehrendCPremixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patientsDiabet Med200219393912027927
   PubMed Web of Science ®Google Scholar
• BolenSFeldmanLVassyJSystematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitusAnn Intern Med2007in press
   PubMed Web of Science ®Google Scholar
• BuseJBTanMHPrinceMJThe effects of oral anti-hyperglycemic medications on serum lipid profiles in patients with type 2 diabetesDiabetes Obes Metab200461335614746579
   PubMed Web of Science ®Google Scholar
• CarstensenMThomsenCGotzscheODifferential postprandial lipoprotein responses in type 2 diabetic men with and without clinical evidence of a former myocardial infarctionRev Diabet Stud200441758417491702
   PubMedGoogle Scholar
• CavalotFPetrelliATraversaMPostprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes StudyJ Clin Endocrinol Metab200691813916352690
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and PreventionNational Diabetes Fact Sheet: National Estimates and General Information on Diabetes in the United States2003AtlantaUS Department of Health and Human Services, Centers for Disease Control and Prevention
   Google Scholar
• CerielloADavidsonJHanefeldMPostprandial hyperglycemia and cardiovascular complications of diabetes: an updateNutr Metab Cardiovasc Dis200616453616934443
   PubMed Web of Science ®Google Scholar
• ChiquetteERamirezGDeFronzoRA meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factorsArch Intern Med2004164209710415505122
   PubMed Web of Science ®Google Scholar
• CoatesVEMonitoring diabetic controlJ Clin Nurs1994326397834136
   PubMedGoogle Scholar
• DavidsonMBStarting insulin therapy in type 2 diabetic patients: does it really matter how?Diabetes Care200528494515677824
   PubMed Web of Science ®Google Scholar
• DaviesMThe reality of glycemic control in insulin treated diabetes: defining the clinical challengesInt J Obes200428Suppl 2S1422
   PubMed Web of Science ®Google Scholar
• DaviesMStormsFShutlerSImprovement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargineDiabetes Care2005281282815920040
   PubMed Web of Science ®Google Scholar
• DavisTMCullCAHolmanRRUK Prospective Diabetes Study (UKPDS) GroupRelationship between ethnicity and glycemic control, lipid profiles, and blood pressure during the first 9 years of type 2 diabetes: UK Prospective Diabetes Study (UKPDS 55)Diabetes Care20012411677411423497
   PubMed Web of Science ®Google Scholar
• De JagerJKooyALehertPHEffects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trialJ Intern Med2005257100915606381
   PubMed Web of Science ®Google Scholar
• DECODE Study Group, for the European Diabetes Epidemiology GroupGlucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteriaArch Intern Med200116139740511176766
   PubMedGoogle Scholar
• DeFronzoRARatnerREHanJEffects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetesDiabetes Care200528109210015855572
   PubMed Web of Science ®Google Scholar
• DeVriesJHNattrassMPieberTRRefining basal insulin therapy: what have we learned in the age of analogues?Diabetes Metab Res Rev2007234415417668418
   PubMed Web of Science ®Google Scholar
• Diabetes Control and Complications Trial Research GroupThe effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitusN Engl J Med1993329977868366922
   PubMed Web of Science ®Google Scholar
• DormandyJACharbonnelBEcklandDJASecondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialLancet200536612798916214598
   PubMed Web of Science ®Google Scholar
• EliaschewitzFGCalvoCValbuenaHHOE 901/4013 LA Study GroupTherapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepirideArch Med Res20063749550116715577
   PubMed Web of Science ®Google Scholar
• FritscheASchweitzerMAHaring HU 4001 Study GroupGlimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trialAnn Intern Med2003138952912809451
   PubMed Web of Science ®Google Scholar
• GaedePVedelPParvingHHIntensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised studyLancet19993536172210030326
   PubMed Web of Science ®Google Scholar
• GaedePPedersenOIntensive integrated therapy of type 2 diabetes: implications for long-term prognosisDiabetes200453S394715561920
   PubMed Web of Science ®Google Scholar
• GarberAJWahlenJWahlTAttainment of glycemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study)Diabetes Obes Metab20068586616367883
   PubMed Web of Science ®Google Scholar
• GoldsteinBJInsulin resistance as the core defect in type 2 diabetes mellitusAm J Cardiol200290310
   PubMed Web of Science ®Google Scholar
• HaffnerJSCassellsHHyperglycemia as a cardiovascular risk factorAm J Med2003115S611
   PubMed Web of Science ®Google Scholar
• HaffnerSMLehtoSRonnemaaTMortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarctionN Engl J Med1998339229349673301
   PubMed Web of Science ®Google Scholar
• HaffnerSMGreenbergASWestonWMEffect of rosiglitazone on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitusCirculation20021066798412163427
   PubMed Web of Science ®Google Scholar
• HanasRLudvigssonJExperience of pain from insulin injections and needle-phobia in young patients with IDDMPract Diab Int199714959
   Google Scholar
• HanefeldMCagatayMPetrowitschTAcarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studiesEur Heart J20042510614683737
   PubMed Web of Science ®Google Scholar
• HanefeldMFischerSJuliusURisk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-upDiabetologia1996391577838960845
   PubMed Web of Science ®Google Scholar
• HarrisMIDiabetes in America: epidemiology and scope of the problemDiabetes Care199821C1149850480
   PubMed Web of Science ®Google Scholar
• HermannLSScherstenBBitzenPOTherapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled studyDiabetes Care199417110097821128
   PubMed Web of Science ®Google Scholar
• HermansenKDaviesMDerezinskiTA 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetesDiabetes Care20062912697416732007
   PubMed Web of Science ®Google Scholar
• HermansenKMortensenLSA review of bodyweight changes associated with antihyperglycemic agents in type 2 diabetesDrug Safety20073011274218035865
   PubMed Web of Science ®Google Scholar
• HermansenKKipnesMLuoESitagliptin Study 035 GroupEfficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metforminDiabetes Obes Metab2007in press
   Web of Science ®Google Scholar
• HiggsERKrentzAJABCD position statement on glitazonesPract Diabetes Int2004212935
   Google Scholar
• HolmanRRThorneKIFarmerAJDaviesMJKeenanJFPaulSLevyJC4-T Study GroupAddition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetesN Engl J Med2007102535717171630 Epub 2007 Sep 217890232
   PubMed Web of Science ®Google Scholar
• JankaHUZieglerAGStandlEDaily insulin dose as a predictor of macrovascular disease in insulin treated non-insulin dependent diabeticsDiabetes Metab19871335964
   Web of Science ®Google Scholar
• KalofoutisCPiperiCZisakiADifferences in expression of cardiovascular risk factors among type 2 diabetes mellitus patients of different ageAnn N Y Acad Sci200610841667717151300
   PubMed Web of Science ®Google Scholar
• KannPHWascherTZackovaVStarting insulin therapy in type 2 diabetes: twice-daily biphasic insulin aspart 30 plus metformin versus once-daily insulin glargine plus glimepirideExp Clin Endocrinol Diabetes20061145273217115351
   PubMed Web of Science ®Google Scholar
• KannelWBThe Framingham Study: its 50-year legacy and future promiseJ Atheroscler Thromb2000660610872616
   PubMedGoogle Scholar
• KannelWBMcGeeDLDiabetes and cardiovascular disease. The Framingham studyJAMA197924120358430798
   PubMed Web of Science ®Google Scholar
• KellyIEHanTSWalshKEffects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetesDiabetes Care1999222889310333947
   PubMed Web of Science ®Google Scholar
• KempfKRoseBHerderCInflammation in metabolic syndrome and type 2 diabetes: Impact of dietary glucoseAnn N Y Acad Sci20061084304817151291
   PubMed Web of Science ®Google Scholar
• KermaniAGargAThiazolidinedione-associated congestive heart failure and pulmonary edemaMayo Clin Proc20037810889112962163
   PubMed Web of Science ®Google Scholar
• KiloCMezitisNJainRStarting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metforminJ Diabetes Complications2003173071314583174
   PubMed Web of Science ®Google Scholar
• KnoppRHWaldenCERetzlaffBMLong-term cholesterol-lowering effects of 4 fat-restricted diets in hypercholesterolemic and combined hyperlipidemic men. The Dietary Alternatives StudyJAMA19972781509159363971
   PubMed Web of Science ®Google Scholar
• KorytkowskiMWhen oral agents fail: practical barriers to starting insulinInt J Obes Relat Metab Disord200226S182412174319
   PubMed Web of Science ®Google Scholar
• KronmalRABarzilayJISmithNLMortality in pharmacologically treated older adults with diabetes: the Cardiovascular Health Study, 1989-2001PLoS Med20063e40017048978
   PubMed Web of Science ®Google Scholar
• KuusistoJMykkanenLPyoralaKNIDDM and its metabolic control predict coronary heart disease in elderly subjectsDiabetes19944396078039603
   PubMed Web of Science ®Google Scholar
• LaaksoMEpidemiology of diabetic dyslipidemiaDiabetes Rev1995340822
   Google Scholar
• LehtoSRonnemaaTHaffnerSMDyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDMDiabetes199746135499231662
   PubMed Web of Science ®Google Scholar
• LemieuxSDespresJPMetabolic complications of visceral obesity: Contribution to the aetiology of type 2 diabetes and implications for prevention and treatmentDiabetes Metab19942037593
   PubMed Web of Science ®Google Scholar
• LieblAPragerRBinzKon behalf of the PREFER study groupThe PREFER Study: both biphasic insulin aspart 30 (BIAsp 30) twice-daily and basal-bolus using insulin detemir (IDet) and insulin aspart (IAsp) enabled patients with type 2 diabetes to achieve A1c target <7.0%Diabetologia200649Suppl 1610
   Google Scholar
• LiuQZKnowlerWCNelsonRGInsulin treatment, endogenous insulin concentration, and ECG abnormalities in diabetic Pima Indians. Cross-sectional and prospective analysesDiabetes1992411141501499865
   PubMed Web of Science ®Google Scholar
• MacfarlaneDPPatersonKRFisherMOral antidiabetic agents as cardiovascular drugsDiabetes Obes Metab20079233017199715
   PubMed Web of Science ®Google Scholar
• MakKHMoliternoDJGrangerCBInfluence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary ArteriesJ Am Coll Cardiol19973017199207639
   PubMed Web of Science ®Google Scholar
• MalmbergKProspective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study GroupBMJ1997314151259169397
   PubMed Web of Science ®Google Scholar
• MalmbergKRydenLEfendicSRandomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 yearJ Am Coll Cardiol19952657657797776
   PubMed Web of Science ®Google Scholar
• MalmbergKRydenLWedelHIntense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidityEur Heart J2005266506115728645
   PubMed Web of Science ®Google Scholar
• MaloneJKKerrLFCampaigneBNLispro Mixture-Glargine Study GroupCombined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapyClin Ther20042620344415823767
   PubMed Web of Science ®Google Scholar
• MaloneJKBaiSCampaigneBNTwice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycemic control in patients with Type 2 diabetesDiabet Med2005223748115787659
   PubMed Web of Science ®Google Scholar
• MansonJENathanDMKrolewskiASA prospective study of exercise and incidence of diabetes among US male physiciansJAMA19922686371608115
   PubMed Web of Science ®Google Scholar
• Massi-BenedettiMFedericiMOCardiovascular risk factors in type 2 diabetes: the role of hyperglycemiaExp Clin Endocrinol Diabetes1999107S120310522835
   PubMed Web of Science ®Google Scholar
• MatherKJVermaSAndersonTJImproved endothelial function with metformin in type 2 diabetes mellitusJ Am Coll Cardiol20013713445011300445
   PubMed Web of Science ®Google Scholar
• MediciFHawaMIanariAConcordance rate for type II diabetes mellitus in monozygotic twins: actuarial analysisDiabetologia1999421465010064093
   PubMed Web of Science ®Google Scholar
• MeeceJPharmacoeconomic advantages of insulin analogs. US Pharm200631HS4250 Available at: http://www.uspharmacist.com/index.asp?show=article&page=8_1920.htm Accessed 30 October 2007
   Google Scholar
• MeigsJBMittlemanMANathanDMHyperinsulinemia, hyperglycemia, and impaired hemostasis: The Framingham Offspring StudyJAMA2000283221810634338
   PubMed Web of Science ®Google Scholar
• MeneghiniLFRosenbergKHKoenenCInsulin detemir improves glycemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE studyDiabetes Obes Metab200794182717391170
   PubMed Web of Science ®Google Scholar
• MonnierLLapinskiHColetteCContributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patientsDiabetes Care200326881512610053
   PubMed Web of Science ®Google Scholar
• MonnierLColetteCDunseathGJThe loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetesDiabetes Care200730263917259492
   PubMed Web of Science ®Google Scholar
• MuisMJBotsMLGrobbeeDEInsulin treatment and cardiovascular disease; friend or foe? A point of viewDiabet Med2005221182615660727
   PubMed Web of Science ®Google Scholar
• NathanDMLachinJClearyPDiabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research GroupIntensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitusN Engl J Med2003348229430312788993
   PubMed Web of Science ®Google Scholar
• NathanDMClearyPABacklundJYDiabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research GroupIntensive diabetes treatment and cardiovascular disease in patients with type 1 diabetesN Engl J Med200535326435316371630
   PubMed Web of Science ®Google Scholar
• NathanDMBuseJBDavidsonMBManagement of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of DiabetesDiabetologia20064917112116802130
   PubMed Web of Science ®Google Scholar
• NissenSEWolskiKEffect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causesN Engl J Med200735624577117517853
   PubMed Web of Science ®Google Scholar
• O’KeefeJHJrMilesJMHarrisWHImproving the adverse cardiovascular prognosis of type 2 diabetesMayo Clin Proc1999741718010069357
   PubMed Web of Science ®Google Scholar
• Philis-TsimikasACharpentierGClausonPComparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetesClin Ther20062815698117157113
   PubMed Web of Science ®Google Scholar
• PolonskyKSGivenBDHirschLJAbnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitusN Engl J Med1988318123193283554
   PubMed Web of Science ®Google Scholar
• PoulsenPKyvikKOVaagAHeritability of type II (non-insulin-dependent) diabetes mellitus and abnormal glucose tolerance – a population-based twin studyDiabetologia1999421394510064092
   PubMed Web of Science ®Google Scholar
• RaskinPAllenEHollanderPInitiating Insulin Therapy in Type 2 Diabetes: a comparison of biphasic and basal insulin analogsDiabetes Care200528260515677776
   PubMed Web of Science ®Google Scholar
• ReavenGMPathophysiology of insulin resistance in human diseasePhysiol Rev199575473867624391
   PubMed Web of Science ®Google Scholar
• RidderstraaleMGudbjoernsdottirSEliassonBObesity and cardiovascular risk factors in type 2 diabetes: results from the Swedish National Diabetes RegisterJ Intern Med20062593142216476109
   PubMed Web of Science ®Google Scholar
• RiddleMCRosenstockJGerichJInsulin Glargine 4002 Study InvestigatorsThe Treat-to-Target Trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patientsDiabetes Care2003263080614578243
   PubMed Web of Science ®Google Scholar
• RidkerPMHennekensCHBuringJEC-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in womenN Engl J Med20003428364310733371
   PubMed Web of Science ®Google Scholar
• Rius RiuFSalinas VertILucas MartínAA prospective study of cardiovascular disease in patients with Type 2 diabetes. 6.3 years of follow-upJ Diabetes Complications2003172354212954150
   PubMed Web of Science ®Google Scholar
• RoachPYueLAroraVHumalog Mix25 Study GroupImproved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulationDiabetes Care19992212586110480767
   PubMed Web of Science ®Google Scholar
• SchalkwijkCGPolandDCvan DijkWPlasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammationDiabetologia199942351710096789
   PubMed Web of Science ®Google Scholar
• SchernthanerGCardiovascular mortality and morbidity in type-2 diabetes mellitusDiabetes Res Clin Pract199631S3138864635
   PubMedGoogle Scholar
• SchrammTKGislasonGRasmussenSCardiovascular morbidity and mortality in diabetes patients receiving glucose reducing treatment: a population-based study of 3.3 million2007American Diabetes Association 2007 Scientific SessionsChicago, IL Poster 692
   Google Scholar
• StamlerJVaccaroONeatonJDDiabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention TrialDiabetes Care199316434448432214
   PubMed Web of Science ®Google Scholar
• St. John SuttonMRendellMDandonaPA comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetesDiabetes Care20022520586412401757
   PubMed Web of Science ®Google Scholar
• StolarMWChiltonRJType 2 diabetes, cardiovascular risk, and the link to insulin resistanceClin Ther200325B43114553864
   PubMed Web of Science ®Google Scholar
• StrattonIMAdlerAINeilAWAssociation of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational studyBMJ2000324051210938048
   PubMedGoogle Scholar
• TurnerRCullCHolmanRfor the UK Prospective Diabetes Study GroupUKPDS 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitusAnn Intern Med1996124136458554206
   PubMed Web of Science ®Google Scholar
• TurnerRCHolmanRRStrattonIMEffect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)Lancet1998352854659742977
   PubMed Web of Science ®Google Scholar
• TurnerRCCullCAFrighiVGlycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirements for multiple therapiesJAMA199928120051210359389
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study GroupIntensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)Lancet1998352837539742976
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study GroupTight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38)BMJ1998317703139732337
   PubMed Web of Science ®Google Scholar
• Van de LaarFALucassenPLBJNo evidence for a reduction of myocardial infarctions by acarbose (Letter)Eur Heart J200425117915231377
   PubMed Web of Science ®Google Scholar
• Van De LaarFALucassenPLAkkermansRPA-Glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysisDiabetes Care2005281546315616251
   PubMed Web of Science ®Google Scholar
• VilsbøllTZdravkovicMLe-ThiTLiraglutide significantly improves glycemic control, and lowers body weight without risk of either major or minor hypoglycemic episodes in subjects with type 2 diabetesDiabetes200655A27
   PubMed Web of Science ®Google Scholar
• WatanabeYSunayamaSShimadaKTroglitazone improves endothelial dysfunction in patients with insulin resistanceJ Atheroscler Thromb200071596311480457
   PubMedGoogle Scholar
• WingRUse of very-low-calorie diets in the treatment of obese persons with non-insulin-dependent diabetes mellitusJ Am Diet Assoc199595569747722192
   PubMedGoogle Scholar
• WolfAMColditzGACurrent estimates of the economic cost of obesity in the United StatesObes Res19986971069545015
   PubMedGoogle Scholar
• WrightAFelix BurdenACPaiseyRBSulfonylurea inadequacy. Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57)Diabetes Care200225330611815505
   PubMed Web of Science ®Google Scholar
• WulffeleMGKooyAZeeuwDThe effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic reviewJ Intern Med200425611415189360
   PubMed Web of Science ®Google Scholar
• Yki-JarvinenHDresslerAZiemenMHOE 901/3002 Study GroupLess nocturnal hypoglycaemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetesDiabetes Care2000231130610937510
   PubMed Web of Science ®Google Scholar